Phase 1/2 study of combination chemotherapy with Carboplatin, nab-Paclitaxel, and Bevacizumab for advanced non-squamous non-small cell lung cancer

Phase 1

• Conditions: on-squamous Non-small-cell Lung Cancer

• Registration Number: JPRN-UMIN000016735
• Lead Sponsor: Hiroshima Asa City Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-03-08
• Study Completion: 2017-11-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

Not provided

Exclusion Criteria

1) Squamous cell lung cancer 2) History of Severe drug allergies. 3) Double malignancies within 5 years 4) Uncontrolled ascites, pleural effusion or cardiac effusion 5) Current history of hemoptysis 6-7) High risk of bleeding or thrombus events 8) Evidence of bleeding diathesis or coagulopathy 9) Current or previous history of Pericardial effusion 10) Superior vena cava syndrome 11) Spinal cord compression 12) Current or previous (within the last 1 year) history of cerebrovascular disease 13) Traumatic fracture of unrecovery 14) History of active infection 15) Scheduled operation 16) Antithrombotic agent 17) Uncontrollable Gastrointestinal ulceration 18) Current or previous (within the last 1 year)history of GI perforation 19) Uncontrollable hypertension 20) Severe cardiac disease 21) Interstitial pneumonia or pulmonary fibrosis detectable on X ray 22) With grade2 or more neuropathy 23) Treatment history of bevacizumab 24) Pregnancy, breastfeeding or suspected of being pregnant 25) HBs positive patient 26) Others judged by attending physician

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PhaseI Recommended Dose PhaseII Response Rate

Secondary Outcome Measures

Name	Time	Method
DCR, PFS, OS, Safety